Patent Number: 6,251,904

Title: Pyrazolopyrimidinone cGMP PDE5 inhibitors for the treatment of sexual dysfunction

Abstract: Compounds of the formulae (IA) and (IB): ##STR1## wherein R.sup.1 is C.sub.1 to C.sub.3 alkyl optionally substituted with phenyl, Het or a N-linked heterocyclic group selected from piperidinyl and morpholinyl; wherein said phenyl group is optionally substituted by one or more substitutents selected from C.sub.1 to C.sub.4 alkoxy; halo; CN; CF.sub.3 ; OCF.sub.3 or C.sub.1 to C.sub.4 alkyl wherein said C.sub.1 to C.sub.4 alkyl group is optionally substituted by C.sub.1 to C.sub.4 haloalkyl or haloalkoxy either of which is substituted by one or more halo atoms; R.sup.2 is C.sub.1 to C.sub.6 alkyl and R.sup.13 is OR.sup.3 or NR.sup.5 R.sup.6, or pharmaceutically or veterinarily acceptable salts thereof, or pharmaceutically or veterinarily acceptable solvates of either entity are potent and selective inhibitors of type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterase (cGMP PDE5) and have utility in the treatment of, inter alia, male erectile dysfunction (MED) and female sexual dysfunction (FSD).

Inventors: Bunnage; Mark Edward (Sandwich, GB), Mathias; John Paul (Sandwich, GB), Street; Stephen Derek Albert (Sandwich, GB), Wood; Anthony (Sandwich, GB)

Assignee: Pfizer Inc.

International Classification: C07D 405/00 (20060101); C07D 405/12 (20060101); C07D 213/00 (20060101); C07D 213/80 (20060101); C07D 401/00 (20060101); C07D 401/12 (20060101); C07D 487/00 (20060101); C07D 487/04 (20060101); C07D 487/04 (); C07D 401/12 (); A61K 031/505 ()

Expiration Date: 06/26/2018